United Kingdom (UK)
Recombinant monoclonal antibody to human Galectin 9. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 1G3.
UniProt Accession Number of Target Protein: O00182
Alternative Name(s) of Target: Galectin-9; Gal-9; LGALS9; Ecalectin; Tumor antigen HOM-HD-21
Immunogen: The original antibody was generated by immunizing BALB/c mice with a recombinant c-terminus galectin-9 (residues 191 to 355 of the galectin-9 long isoform).
Specificity: This antibody is specific for human Gal-9 but exhibits cross-binding of murine Gal-9.
Application Notes: The binding and binding specificity of the original format of this antibody to c-terminus Gal-9 were assessed via ELISA. Epitope mapping was also done using ELISA. Furthermore, this antibody was successfully used in WB and IHC assays (Barjon et al., 2012; PMID: 22805533). An scFv-CAR version of this antibody with therapeutic potential was developed and described (US20230295564A1). This antibody was successfully used to neutralize LGALS9 in a study focused on pancreatic neoplastic lesions (Quilbe et al., 2023; PMID: 38098486). This antibody was used in a T lymphocyte proliferation assay, specifically in assessing the immunomodulatory properties of extracellular vesicles (C15SEVs) derived from nasopharyngeal carcinoma and recombinant Galectin-9S. In this assay, the antibody was used to block the impact of C15SEVs and recombinant Galectin-9 on peripheral blood mononuclear cells (Lefebvre et al., 2023; PMID: 38117000).
Antibody first published in:
Barjon et al. A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses. Infect Agent Cancer. 2012 Jul 17;7(1):16. PMID:22805533
Note on publication:
The original publication presents the development of monoclonal antibodies targeting galectin-9 and focuses on the development and characterization of a novel monoclonal antibody, 1G3, with a particular emphasis on its application in improving the detection and understanding of galectin-9 expression in clinical samples.